

26 June 2024

Privatisation by way of merger

Disclosure of dealings in the shares of Shanghai Henlius Biotech, Inc.

The Executive received the following disclosure of securities dealings pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers:

Party	Date	Description of relevant securities	Description of products	Nature of dealings	Number of reference securities to which the derivatives relate	Maturity date / closing out date	Reference price	Total amount paid / received	Resultant balance (including those of any person with whom there is an agreement or understanding)
China International Capital Corporation Limited	25 June 2024	Derivatives	Other types of products	Closing out of a derivative contract	117,800	25 June 2024	\$22.3088	\$2,627,976.6400	0
		Derivatives	Other types of products	Closing out of a derivative contract	117,800	25 June 2024	\$22.3088	\$2,627,976.6400	0

End



Note:

China International Capital Corporation Limited is an exempt principal trader connected with the Offeror.

Dealings were made for its own account.

China International Capital Corporation Limited is ultimately owned by China International Capital Corporation Limited.